Literature DB >> 12878505

Pharmacokinetics and metabolism of [14C]viramidine in rats and cynomolgus monkeys.

Chin-Chung Lin1, Kenneth Luu, David Lourenco, Li-Tain Yeh.   

Abstract

The pharmacokinetics of [(14)C]viramidine, a prodrug of ribavirin, were studied in rats (30 mg/kg of body weight) and monkeys (10 mg/kg) following intravenous (i.v.) and oral administration. The levels of oral absorption and bioavailabilities were 61.7 and 9.91%, respectively, in rats and 43.9 and 13.6%, respectively, in monkeys. Following i.v. administration, the elimination half-lives were 2.7 h in rats and 28.9 h in monkeys. Total body clearances were 14.0 liters/h/kg in rats and 1.23 liters/h/kg in monkeys; the apparent volumes of distribution were 15.6 liters/kg in rats and 18.6 liters/kg in monkeys. Following oral administration, viramidine was extensively converted to ribavirin, followed by further metabolism of ribavirin in both species, with a faster rate of metabolism in rats than in monkeys. In rats, excretion of total radioactivity in urine accounted for 77.0% of the i.v. dose and 60.8% of the oral dose, while in monkeys it accounted for 44.4% of the i.v. dose and 39.0% of the oral dose. The amount of unchanged viramidine and ribavirin in urine was small in both species after i.v. and oral administration of viramidine.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12878505      PMCID: PMC166067          DOI: 10.1128/AAC.47.8.2458-2463.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  Pharmacokinetics and metabolism of [(14)C]ribavirin in rats and cynomolgus monkeys.

Authors:  Chin-Chung Lin; Li-Tain Yeh; Trong Luu; David Lourenco; Johnson Y N Lau
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

2.  The relationship between the metabolism of ribavirin and its proposed mechanism of action.

Authors:  J P Miller; L J Kigwana; D G Streeter; R K Robins; L N Simon; J Roboz
Journal:  Ann N Y Acad Sci       Date:  1977-03-04       Impact factor: 5.691

3.  Pharmacokinetics and long-term tolerance to ribavirin in asymptomatic patients infected with human immunodeficiency virus.

Authors:  J J Lertora; A B Rege; J T Lacour; N Ferencz; W J George; R B VanDyke; K C Agrawal; N E Hyslop
Journal:  Clin Pharmacol Ther       Date:  1991-10       Impact factor: 6.875

4.  The metabolism of ribavirin in erythrocytes and nucleated cells.

Authors:  T Page; J D Connor
Journal:  Int J Biochem       Date:  1990

5.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

6.  Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide.

Authors:  R W Sidwell; J H Huffman; G P Khare; L B Allen; J T Witkowski; R K Robins
Journal:  Science       Date:  1972-08-25       Impact factor: 47.728

7.  Safety, tolerance, and pharmacokinetics of systemic ribavirin in children with human immunodeficiency virus infection.

Authors:  E Connor; S Morrison; J Lane; J Oleske; R L Sonke; J Connor
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

8.  Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)

Authors:  T Poynard; P Marcellin; S S Lee; C Niederau; G S Minuk; G Ideo; V Bain; J Heathcote; S Zeuzem; C Trepo; J Albrecht
Journal:  Lancet       Date:  1998-10-31       Impact factor: 79.321

9.  Activation and deactivation of a broad-spectrum antiviral drug by a single enzyme: adenosine deaminase catalyzes two consecutive deamination reactions.

Authors:  Jim Zhen Wu; Heli Walker; Johnson Y N Lau; Zhi Hong
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

10.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

Authors:  J G McHutchison; S C Gordon; E R Schiff; M L Shiffman; W M Lee; V K Rustgi; Z D Goodman; M H Ling; S Cort; J K Albrecht
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245

View more
  7 in total

1.  Dual-action mechanism of viramidine functioning as a prodrug and as a catabolic inhibitor for ribavirin.

Authors:  Jim Zhen Wu; Gary Larson; Zhi Hong
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

Review 2.  Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond?

Authors:  Katherine L B Borden; Biljana Culjkovic-Kraljacic
Journal:  Leuk Lymphoma       Date:  2010-10

3.  Absorption, metabolism, and excretion of [14C]viramidine in humans.

Authors:  Chin-Chung Lin; Christine Xu; Nanqun Zhu; Li-Tain Yeh
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

4.  Disposition and metabolic profiles of [14C]viramidine and [14C]ribavirin in rat and monkey red blood cells and liver.

Authors:  Chin-Chung Lin; David Lourenco; Guifen Xu; Li-Tain Yeh
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

5.  HPLC-MS/MS method for the intracellular determination of ribavirin monophosphate and ribavirin triphosphate in CEM ss cells.

Authors:  Margarita Meléndez; Osvaldo Rosario; Beatriz Zayas; José F Rodríguez
Journal:  J Pharm Biomed Anal       Date:  2009-02-13       Impact factor: 3.935

6.  Feasibility of ribavirin therapeutic drug monitoring in hepatitis C.

Authors:  Francois-Ludovic Sauvage; Francoise Stanke-Labesque; Marie-Claude Gagnieu; Jean-Francois Jourdil; Gerard Babany; Pierre Marquet
Journal:  Ther Drug Monit       Date:  2009-06       Impact factor: 3.681

7.  Randomised clinical trial: pre-dosing with taribavirin before starting pegylated interferon vs. standard combination regimen in treatment-naïve patients with chronic hepatitis C genotype 1.

Authors:  M Palmer; R Rubin; V Rustgi
Journal:  Aliment Pharmacol Ther       Date:  2012-06-19       Impact factor: 8.171

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.